Compare BioNano Genomics Inc (BNGO) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Bank of New York Mellon Corp — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Bank of New York Mellon Corp trades at $159.87 (market cap $106.05B). The key difference: Bank of New York Mellon Corp is far larger — about 8034.1× BioNano Genomics Inc's market cap, and Bank of New York Mellon Corp pays a 1.37% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | BNY | |
|---|---|---|
Market Cap | $13.20M | $106.05B |
Sector | Health | Financials |
52-Week High | $4.92 | $154.50 |
52-Week Low | $1.09 | $95.16 |
Enterprise Value | $15.81M | — |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
BNY trades at $151.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue growth has been steady, rising from $16.0B in 2022 to $19.8B in 2025, while net income margin improved to 29.21%. Analyst consensus is mixed with 38% buy ratings but a $156 price target suggesting modest upside. Recent news highlights strong fee income expectations and a planned 19% dividend increase.
BNY demonstrates solid fundamental strength with improving profitability and consistent earnings beats. The stock offers potential upside to analyst targets and dividend growth, but faces risks from high investing cash outflows and competitive pressures. Current valuation metrics appear reasonable relative to historical performance, though investors should monitor Q2 earnings results for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
